Company intelligence / Profile preview

CNPharm

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

CNPharm has demonstrated in vivo that their Niclosamide formulations (oral and injectable) sustain blood levels above the antiviral IC50/IC100 for >12–24 hours in animal models; as of mid-2021, they were preparing for clinical trials, but no human clinical data reported yet.[1][2][3][4]

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeDrug delivery system
Industry: Biotech

Drug pipeline

1 asset

Polyplatin

Preclinical

Partnerships

Hyundai Bioscience (parent/major shareholder)Knotus (non-clinical CRO provider for animal studies)[2]

Beyond the preview

Go deeper on CNPharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNPharm.

Explore the full profile